Ophthalmology
| Product Candidate |
Proprietary Platform |
Indication |
Development Stage |
Years IP |
Prevalence (Millions) |
|
Discovery |
Pre‑Clinical |
Phase I |
Phase II/III |
|
| ND10Oral |
7-MX |
UV-B Cataract Prevention |
|
20 |
3+ (US) / 15+ (GL) |
| ND10Eye Drop |
7-MX |
Dry Eye Disease |
|
20 |
35+ (US) / 700+ (GL) |
| ND10ER, Oral |
7-MX |
High Myopia Control |
|
20 |
1.2+ (US) / 35+ (GL) |
| rHCT3-1Film/Implant |
rHCT3 |
Corneal Blindness |
|
20 |
2+ (US) / 12.7 (GL) |
| rHCT3-2Eye Drops |
rHCT3 |
Keratoconus |
|
20 |
0.5+ (US) / 9.6 (GL) |
| XP37Back Eye Drop |
XP |
Neo Vascular AMD |
|
20 |
1.75 (US) / 200 (GL) |
| XP37Back Eye Drop |
XP |
Pterygium |
|
20 |
10 (US) / 200 (GL) |
